Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 1.00 |
| ▸ | ATM | Q13315 | 1/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.71 |
| ▸ | P4HB | P07237 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 6/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.55 |
| ▸ | HTT | P42858 | 4/20 | 0.55 |
| ▸ | TP53 | P04637 | 3/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | BRAF | P15056 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29549198 | 1.00 | KMT2A (1.00) | KMT2AHSP90AA1ATMMCL1P4HB | |
| SCHEMBL24089085 | 0.88 | KMT2A (0.78) | KMT2AHSP90AA1ATMMCL1P4HB | |
| SCHEMBL16696558 | 0.87 | KMT2A (0.78) | KMT2AHSP90AA1ATMMCL1P4HB | |
| SCHEMBL30868623 | 0.87 | P4HB (0.78) | KMT2AHSP90AA1ATMMCL1P4HB | |
| SCHEMBL16697070 | 0.85 | KMT2A (0.74) | KMT2AHSP90AA1ATMMCL1P4HB | |
| SCHEMBL16696529 | 0.85 | HSP90AA1 (0.74) | KMT2AHSP90AA1ATMMCL1P4HB | |
| SCHEMBL16696545 | 0.85 | KMT2A (0.73) | KMT2AHSP90AA1ATMMCL1P4HB | |
| SCHEMBL16696534 | 0.84 | KMT2A (0.72) | KMT2AHSP90AA1ATMMCL1P4HB | |
| SCHEMBL15781873 | 0.83 | ALDH1A1 (0.79) | KMT2AHSP90AA1ATMMCL1P4HB | |
| SCHEMBL24505632 | 0.82 | KMT2A (0.70) | KMT2AHSP90AA1ATMMCL1P4HB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2863920-B1 | QUINOLINE DERIVATIVES FOR USE IN THE TRATMENT OF BREAST CANCER | EUTROPICS PHARMACEUTICALS INC (US) | 2023-03-22 | — | — | EP | claimed |
| US-20180221366-A1 | METHODS AND COMPOSITIONS USEFUL FOR TREATING DISEASES INVOLVING BCL-2 FAMILY PROTEINS WITH QUINOLINE DERIVATIVES | EUTROPICS PHARMACEUTICALS, INC. | 2018-08-09 | — | — | US | claimed |
| US-20150150869-A1 | METHODS AND COMPOSITIONS USEFUL FOR TREATING DISEASES INVOLVING BCL-2 FAMILY PROTEINS WITH QUINOLINE DERIVATIVES | EUTROPICS PHARMACEUTICALS, INC. | 2015-06-04 | — | — | US | claimed |
| US-20150133450-A1 | METHODS AND COMPOSITIONS USEFUL FOR TREATING DISEASES INVOLVING BCL-2 FAMILY PROTEINS WITH QUINOLINE DERIVATIVES | EUTROPICS PHARMACEUTICALS INC (US) | 2015-05-14 | — | — | US | claimed |
| EP-2863920-B1 | QUINOLINE DERIVATIVES FOR USE IN THE TRATMENT OF BREAST CANCER | EUTROPICS PHARMACEUTICALS INC (US) | 2023-03-22 | — | — | EP | disclosed |
| US-20210379078-A1 | Killing Senescent Cells And Treating Senescence-Associated Conditions Using A Bcl Inhibitor And An Mcl-1 Inhibitor | UNITY BIOTECHNOLOGY, INC. | 2021-12-09 | — | — | US | disclosed |
| US-20210299128-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | RIKEN (JP) | 2021-09-30 | — | — | US | disclosed |
| WO-2021188417-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | FLASH THERAPEUTICS, LLC (US) | 2021-09-23 | — | — | WO | disclosed |
| US-10765673-B2 | Methods and compositions useful for treating diseases involving Bcl-2 family proteins with quinoline derivatives | EUTROPICS PHARMACEUTICALS, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10413549-B2 | Methods and compositions useful for treating diseases involving Bcl-2 family proteins with isoquinoline and quinoline derivatives | EUTROPICS PHARMACEUTICALS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20180221366-A1 | METHODS AND COMPOSITIONS USEFUL FOR TREATING DISEASES INVOLVING BCL-2 FAMILY PROTEINS WITH QUINOLINE DERIVATIVES | EUTROPICS PHARMACEUTICALS, INC. | 2018-08-09 | — | — | US | disclosed |
| EP-2922544-B1 | METHODS AND COMPOSITIONS USEFUL FOR TREATING DISEASES INVOLVING BCL-2 FAMILY PROTEINS WITH QUINOLINE DERIVATIVES | EUTROPICS PHARMACEUTICALS INC (US) | 2018-08-01 | — | — | EP | disclosed |
| US-20140134163-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | Errico, Joseph P. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8658170-B2 | Combination therapy with MDM2 and EFGR inhibitors | Errico, Joseph P. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658170-B2 | Combination therapy with MDM2 and EFGR inhibitors | Errico, Joseph P. (US) | 2014-02-25 | — | — | US | disclosed |
| US-20120156197-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | Errico, Joseph P. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120156197-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | Errico, Joseph P. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012012653-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | ERRICO JOSEPH P (US) | 2012-01-26 | — | — | WO | disclosed |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10765673-B2 | Methods and compositions useful for treating diseases involving Bcl-2 family proteins with quinoline derivatives | BCL3, BCL6, MCL1 | KMT2A 720/4885HSP90AA1 859/4885ATM 4037/4885 |
| US-20180221366-A1 | METHODS AND COMPOSITIONS USEFUL FOR TREATING DISEASES INVOLVING BCL-2 FAMILY PROTEINS WITH QUINOLINE DERIVATIVES | BCL3, BCL6, MCL1 | KMT2A 720/4885HSP90AA1 859/4885ATM 4037/4885 |
| US-20120156197-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | TP53, EGFR, MDM2 | KMT2A 3490/4885HSP90AA1 356/4885ATM 335/4885 |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | KMT2A 3667/4885HSP90AA1 961/4885ATM 3462/4885 |
| US-20150150869-A1 | METHODS AND COMPOSITIONS USEFUL FOR TREATING DISEASES INVOLVING BCL-2 FAMILY PROTEINS WITH QUINOLINE DERIVATIVES | BCL3, BCL6, MCL1 | KMT2A 720/4885HSP90AA1 859/4885ATM 4037/4885 |
| US-20210379078-A1 | Killing Senescent Cells And Treating Senescence-Associated Conditions Using A Bcl Inhibitor And An Mcl-1 Inhibitor | MCL1, BCL2, BCL2L1 | KMT2A 2776/4885HSP90AA1 1692/4885ATM 829/4885 |
| US-10413549-B2 | Methods and compositions useful for treating diseases involving Bcl-2 family proteins with isoquinoline and quinoline derivatives | BCL3, MCL1, BCL6 | KMT2A 751/4885HSP90AA1 513/4885ATM 3416/4885 |
| US-20140134163-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | TP53, EGFR, MDM2 | KMT2A 3490/4885HSP90AA1 356/4885ATM 335/4885 |
| US-20210299128-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | MCL1, FLT3, ABL1 | KMT2A 115/4885HSP90AA1 1836/4885ATM 878/4885 |
| US-20150133450-A1 | METHODS AND COMPOSITIONS USEFUL FOR TREATING DISEASES INVOLVING BCL-2 FAMILY PROTEINS WITH QUINOLINE DERIVATIVES | BCL3, BCL6, MCL1 | KMT2A 720/4885HSP90AA1 859/4885ATM 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.